CLB Stock Recent News
CLB LATEST HEADLINES
While the top- and bottom-line numbers for Core Laboratories (CLB) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
In the investment space, uncovering stocks to sell with potential pitfalls is as crucial as identifying opportunities. This comprehensive review zooms in on the recent moves of three prominent companies that have sent ripples through the market.
Core Laboratories (CLB) anticipates revenues in the range of $125-$132 million and operating income in the band of $13.8-$17.3 million for the fourth quarter of 2023. It also expects earnings per share in the 17-23 cents range.
Although the revenue and EPS for Core Laboratories (CLB) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Crude price is now in its glorious days, calling for investment in energy companies like Matador Resources (MTDR), Pioneer Natural (PXD) and Core Laboratories (CLB).
The decisions of Saudi Arabia & Russia to voluntarily extend oil cuts until the year-end are aiding the crude rally. Solaris (SOI), Core Lab (CLB) and Evolution (EPM) are thus well-poised to gain.
Core Laboratories (CLB) anticipates revenues and operating income in the range of $128-$132 million and $15.2-$17.5 million, respectively, with earnings in the band of 21-25 cents per share for Q3 2023.
The headline numbers for Core Laboratories (CLB) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Core Laboratories (CLB) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.12 per share a year ago.
Business is improving for Core Laboratories Inc. at a very modest incremental pace. The company lacks a moat or a near-term catalyst.